PL2094849T3 - Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących - Google Patents

Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących

Info

Publication number
PL2094849T3
PL2094849T3 PL07871436T PL07871436T PL2094849T3 PL 2094849 T3 PL2094849 T3 PL 2094849T3 PL 07871436 T PL07871436 T PL 07871436T PL 07871436 T PL07871436 T PL 07871436T PL 2094849 T3 PL2094849 T3 PL 2094849T3
Authority
PL
Poland
Prior art keywords
long term
immunostimulatory oligonucleotides
term disease
disease modification
modification
Prior art date
Application number
PL07871436T
Other languages
English (en)
Inventor
Edith Hessel
Robert L Coffman
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Publication of PL2094849T3 publication Critical patent/PL2094849T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL07871436T 2006-11-09 2007-11-09 Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących PL2094849T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86508906P 2006-11-09 2006-11-09
PCT/US2007/084358 WO2008073661A2 (en) 2006-11-09 2007-11-09 Long term disease modification using immunostimulatory oligonucleotides
EP07871436.7A EP2094849B1 (en) 2006-11-09 2007-11-09 Long term disease modification using immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
PL2094849T3 true PL2094849T3 (pl) 2014-06-30

Family

ID=39512389

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07871436T PL2094849T3 (pl) 2006-11-09 2007-11-09 Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących

Country Status (10)

Country Link
US (1) US8252757B2 (pl)
EP (1) EP2094849B1 (pl)
JP (2) JP5714818B2 (pl)
CN (2) CN104857512A (pl)
AU (1) AU2007333368C1 (pl)
CA (1) CA2669137A1 (pl)
DK (1) DK2094849T3 (pl)
ES (1) ES2454175T3 (pl)
PL (1) PL2094849T3 (pl)
WO (1) WO2008073661A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4598389B2 (ja) * 2001-06-21 2010-12-15 ダイナバックス テクノロジーズ コーポレイション キメラ免疫調節化合物とその使用方法
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
KR20120128729A (ko) * 2002-12-23 2012-11-27 다이나박스 테크놀로지 코퍼레이션 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2008073661A2 (en) * 2006-11-09 2008-06-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
AU2009246169B2 (en) 2008-05-15 2015-01-22 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2018147265A1 (ja) * 2017-02-07 2018-08-16 京都府公立大学法人 病原性グラム陰性菌に対するワクチン
CN113412273A (zh) * 2019-01-07 2021-09-17 川斯勒佰尔公司 用于治疗原发性纤毛运动障碍的组合物和方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5093232A (en) * 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5452496A (en) * 1994-02-03 1995-09-26 Schuller International, Inc. Vacuum assisted accumulator and process of collecting microfiber
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69739515D1 (de) 1996-01-30 2009-09-10 Univ California Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
DE69837094T2 (de) 1997-09-05 2007-08-30 The Regents Of The University Of California, Oakland Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040132677A1 (en) * 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
KR20120128729A (ko) 2002-12-23 2012-11-27 다이나박스 테크놀로지 코퍼레이션 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
US7718622B2 (en) 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
WO2008073661A2 (en) 2006-11-09 2008-06-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides

Also Published As

Publication number Publication date
AU2007333368A1 (en) 2008-06-19
US20090068208A1 (en) 2009-03-12
CA2669137A1 (en) 2008-06-19
JP2010509371A (ja) 2010-03-25
JP6023142B2 (ja) 2016-11-09
AU2007333368B2 (en) 2013-07-18
WO2008073661A3 (en) 2009-02-12
WO2008073661A2 (en) 2008-06-19
EP2094849B1 (en) 2014-01-08
JP2015028066A (ja) 2015-02-12
ES2454175T3 (es) 2014-04-09
JP5714818B2 (ja) 2015-05-07
AU2007333368C1 (en) 2014-03-13
US8252757B2 (en) 2012-08-28
DK2094849T3 (en) 2014-03-24
EP2094849A2 (en) 2009-09-02
CN101636495A (zh) 2010-01-27
CN104857512A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
PL2094849T3 (pl) Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących
TWI370740B (en) Immunostimulatory oligonucleotides
PT1957647E (pt) Oligorribonucleótidos imunoestimulantes
EP2021399A4 (en) BIOLOGICAL POLYSILOXANE
GB0607088D0 (en) Vaccine
GB0504436D0 (en) Vaccine
IL197433A0 (en) Fillings
GB0619182D0 (en) Oligonucleotide arrays
PT1907574E (pt) Oligonucleótidos
HK1129836A1 (zh) 疫苗
EP1908829A4 (en) OLIGONUCLEOTIDE PROBE
EP2113511A4 (en) DNA VACCINES FOR FISH
ZA200901592B (en) Vaccine
ZA200804303B (en) Immunostimulatory oligoribonucleotides
GB0625593D0 (en) Vaccine
AU3682P (en) DC101 Dianella caerulea
GB0614476D0 (en) Vaccine
GB0619821D0 (en) Vaccine
GB0620336D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0619824D0 (en) Vaccine
GB0619822D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0608962D0 (en) Vaccine
GB0620815D0 (en) Vaccine